Grant cycle
A lab or diagnostics group gets funded and reagent demand moves before the team sees a purchase signal.
For Reagent and specialty suppliers
Nobody announces they're switching.
ARIA finds where that budget sits, flags substitution risk before reorder volume drops, and prepares the account-specific reason to call.
Buying windows ARIA watches
ARIA watches four triggers for reagent and specialty suppliers, each visible before demand shows up in a purchase order or CRM.
A lab or diagnostics group getting funded. A new assay or validation path opening a supply conversation. A key account beginning to compare alternatives. A budget window where spend is live while wider demand still looks soft.
Spec-in window
A program in development locks its materials in early, often by Phase 1. The reagent validated now rides the program.
Substitution risk
A key account starts comparing alternative reagents before reorder volume drops.
Budget window
A lab has active spend now, while broader market demand still looks soft.
Award money arrives in annual tranches
NIH funds an award one budget period at a time, and a budget period is usually 12 months, so spending capacity resets rather than arriving at once.
A headline award figure is not a pot of money the lab can spend now. NIH defines a budget period as the interval from the start date of a funded portion of an award to its end date, usually 12 months, which means a multi-year award is released in yearly segments. Where an account sits inside its current segment therefore changes what is worth a call more than the total award size does.
Source: NIH Grants Policy Statement. ARIA reads the primary record, not a summary of it, and links each claim back to the filing it came from.
How to rank the accounts worth working
Rank on four things: how recent the award is, where the account sits in its budget period, substitution risk on accounts you hold, and work fit.
Rank on four things. How recently the account was funded, where it sits in the budget period that funding covers, whether an account you already hold is being evaluated against an alternative, and whether the funded work actually uses what you sell. Money and fit decide the order.
Award recency
Public award records carry a notice date and an amount, so a newly funded lab is identifiable and a lab still waiting is too. Recency matters more here than size, because a large award granted two years ago has usually already been committed to standing suppliers.
Position in the budget period
Federal awards are funded one budget period at a time, and a budget period is usually twelve months. An account early in a period has spend ahead of it. An account late in one is mostly working through commitments already made, which changes what is worth a call now.
Substitution exposure
Substitution starts with an evaluation, not with a cancelled order. A new assay, a validation path, or a protocol change on an account you already hold is a live risk with a clock on it, and it outranks a cold account that merely looks well funded.
Fit to the work
An award only matters if the research it funds uses what you supply. Score each funded account against the assays and workflows you actually serve, so the team spends its calls on labs that can buy from you rather than labs that simply received money.
ARIA scores each account on these and shows the evidence behind the score, so the person reviewing it can disagree. Nothing is contacted without a person approving it first.
What ARIA prepares for you
For each, ARIA prepares an account-specific reason to call, a reorder-defense note, and budget-window outreach, staged for approval.
The reorder-defense note only appears where substitution risk actually shows up in the signal. Each claim is sourced to the grant or filing it came from.
Account-specific reason to callReorder defense noteBudget-window outreach
A live deal, with the technical wedge to win it.
Your firm, your modality, your region. ARIA finds a live commercial opening, reasons the technical wedge to win it, and stages the outreach.
Reasoning trace
- Point ARIA at your firm and run. It finds a real recruiting program and prepares the read here, each step sourced.
Sourced where a source exists · held back where none does
Prepared readTriangulated
Prepared for your firm
Reach the lab when the budget lands
Point ARIA at your firm and run. A lab that was just funded, the consumable read, and your first-call question compose in right here, every claim sourced.
CDMO business development
The right programs, not more leads.
ARIA scores fresh raises, phase changes, and de-risking sponsors against your capability and open capacity, then drafts the outreach.
ARIA watches
Funding event
A target biotech raises or extends runway before your BD team knows to reach out.
Phase change
A lead program advances and the sponsor starts pressure-testing manufacturing capacity.
New CMC owner
A new technical decision-maker resets vendor preference and partner selection.
Supply-chain de-risking
A sponsor starts reducing dependence on one geography or one incumbent CDMO.
ARIA prepares
Program-fit briefCapacity-timed outreachCRM opportunity note
You approve
Every claim sourced. Nothing sends on its own.
Bioprocessing equipment and consumables
Place instruments ahead of the curve.
ARIA flags the funded programs that are scaling, and surfaces competitive moves on your installed base before they cost you a reorder.
ARIA watches
Spec-in window
A process characterized on your platform tends to scale on it. The vendor is chosen when the URS is written, not at the PO.
Competitor quote
A rival appears in an installed-base account before your rep knows the account is evaluating.
Reorder window
Consumable pull-through starts to slip across sites before renewal risk shows in CRM.
Capacity expansion
A facility or suite expansion creates equipment demand before the budget is public.
ARIA prepares
Equipment-fit briefCompetitive save motionRep-ready talk track
You approve
Every claim sourced. Nothing sends on its own.
Reagent and specialty suppliers
Nobody announces they're switching.
ARIA finds where that budget sits, flags substitution risk before reorder volume drops, and prepares the account-specific reason to call.
ARIA watches
Grant cycle
A lab or diagnostics group gets funded and reagent demand moves before the team sees a purchase signal.
Spec-in window
A program in development locks its materials in early, often by Phase 1. The reagent validated now rides the program.
Substitution risk
A key account starts comparing alternative reagents before reorder volume drops.
Budget window
A lab has active spend now, while broader market demand still looks soft.
ARIA prepares
Account-specific reason to callReorder defense noteBudget-window outreach
You approve
Every claim sourced. Nothing sends on its own.
Life sciences consultants
Be the first call, not the second opinion.
ARIA tracks partner movement, buyer changes, and competitive context across the sponsors you serve, and turns it into a sourced brief or client update.
ARIA watches
Partner search
A sponsor begins comparing CDMO, tools, or supply partners before the shortlist is visible.
Portfolio movement
A company you cover changes phase, funding, buyer, or manufacturing plan.
New decision-maker
A new BD, CMC, or strategy owner changes who should be reached.
Competitive move
A competitor, partner, or supplier changes the account landscape.
ARIA prepares
Sourced partner briefAccount context readoutClient follow-up draft
You approve
Every claim sourced. Nothing sends on its own.
Questions buyers ask
- How do reagent suppliers find labs with active budget?
- Funding is the budget signal, and it is public: grant awards to academic and core labs, and financing rounds for scaling biotechs. ARIA monitors both and identifies the accounts that can still buy in a market where broader demand looks soft.
- How does NIH award funding actually reach a lab?
- In annual tranches, not as a lump sum. NIH defines a budget period as the interval from the start date of a funded portion of an award to its end date, usually 12 months, so a multi-year award is released in yearly segments. A headline award figure therefore overstates what a lab can spend right now, and where an account sits inside its current budget period matters more than the total award size.
- What signals show a lab just received funding?
- Federal grant awards carry a notice date and an award amount, and newly financed biotechs file publicly when they raise. Both appear well before the resulting purchasing behaviour becomes visible to a supplier.
- How should reagent suppliers prioritise accounts?
- Rank on four inputs. How recently the account was funded, since award records carry a notice date and recency matters more than size. Where the account sits in the budget period that funding covers, because federal awards are issued one year at a time and an account early in a period still has spend ahead of it. Whether an account you already hold is being evaluated against an alternative. And whether the funded work actually uses what you supply.
- How do I defend against reagent substitution?
- Substitution usually starts with evaluation, not with a cancelled order. A new assay, a validation path, or a protocol change creates the opening. Surfacing those account-level changes early turns a defensive reorder conversation into a timely technical one.
- Does ARIA contact prospects on its own?
- No. It prepares sourced, account-specific work and stages it. A person approves everything that goes out.
Put ARIA on your accounts.
One workflow, your systems, your team's approval. Book a short walkthrough and see your first pass.